1991
DOI: 10.1007/bf01744267
|View full text |Cite
|
Sign up to set email alerts
|

A need to intensify drug surveillance in Germany

Abstract: Despite all its limitations, the spontaneous reporting system still forms the basis for drug safety assessments in the Federal Republic of Germany. Although there have been some promising attempts to standardise the methodology of detecting, analysing and evaluating adverse drug events (ADEs) in certain clinico-pharmacological institutes and psychiatric departments, the approaches have not been integrated and are used only locally. The only exception is the Freiburg Documentation Centre for Severe Skin Disease… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

1995
1995
2015
2015

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 14 publications
0
2
0
Order By: Relevance
“…For middle age patients, metabolichutritional events were the second most common reported complaints for France. (19)(20)(21)(22)(23)(24)(25)(26)(27). In addition, the level of socialized medicine practices in these countries may also have an impact on the frequency as well as the type of events reported (28).…”
Section: Resultsmentioning
confidence: 99%
“…For middle age patients, metabolichutritional events were the second most common reported complaints for France. (19)(20)(21)(22)(23)(24)(25)(26)(27). In addition, the level of socialized medicine practices in these countries may also have an impact on the frequency as well as the type of events reported (28).…”
Section: Resultsmentioning
confidence: 99%
“…Another example of active surveillance comes in the form of monitoring patients during their stay in hospital. Hospital monitoring of adverse reactions in patients undergoing treatment were reported in Germany, Mexico and India (Kapp et al 1991, Juarez & Olguin 2007and Khairnar & Gade 2011. Hospital monitoring schemes involved; increasing awareness of both doctors and patients about Pharmacovigilance and potential adverse reactions, and improving methods for validation of adverse events (Kapp et al 1991), such as better expert review systems for reviewing adverse reaction reports.…”
mentioning
confidence: 99%